Covaxin output may hit 100 million doses per month by November
Bharat Biotech’s Covaxin production is expected to reach 100 million doses per month by November, against the September timeline estimated by the government. The pace of technology transfer to designated public sector enterprises (PSEs) is being cited by officials as one reason for the delay.
They said, however, that reports from other vaccine makers are encouraging and there shouldn’t be any concerns about overall production. The government machinery is pushing hard to ensure adequate vaccine supply.
“For Covaxin, we will see a significant (production) ramp-up of more than double in August-September, when the doses manufactured by will jump to 5 crore, from the current 2 crore doses, as their Bengaluru facility starts producing in full swing,” a senior government official told ET.
The government had said in an affidavit to the Supreme Court last month that Covaxin’s monthly production was at 20 million doses.
The official added that the second ramp-up is expected around November-December, when public sector units are expected to start producing an additional 30-40 million doses.
Source: Economic Times